T. Rowe Price Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

T. Rowe Price Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.4M	Buy	+2,511,887	New	+$24.5M	0.02%	472

Other funds holding FDMT

JTL

Jupiter Topco LLC New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Investment Management's FDMT Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 2,511,887 shares worth $33.4M. The stake represents 0.02% of the portfolio and ranks #472 among its holdings.

149 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

T. Rowe Price Investment Management held 2,511,887 shares of 4D Molecular Therapeutics worth $33.4M as of Q2 2026.
4D Molecular Therapeutics was a new T. Rowe Price Investment Management position in Q2 2026.
4D Molecular Therapeutics made up 0.02% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #472 holding.
149 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.